The SOLSTICE clinical study is the largest multi-center prospective trial focused on the clinical use and effectiveness of cryotherapy treatments for patients with primary cancer lesions that have metastasized to the lung.

The study calls for two years of follow up, with a projected enrollment of approximately 125 patients. This study follows on Galil Medical’s successful ECLIPSE (Evaluating Cryoablation of Metastatic Lung/Pleura Tumors in Patients – Safety and Efficacy) clinical research study, which reported on 40 subjects in 2013 and is continuing in its patient follow-up stage.

Galil Medical president and CEO Martin J Emerson noted the company is thrilled that many of the leading oncology institutions across the US and Europe are participating in this milestone clinical trial focused on treating a patient population that the company believes it will benefit from cryoablation solutions.

"SOLSTICE, as well as our other clinical studies and active R&D pipeline, will further cement that Galil is the only company in the world solely committed to advancing cryotherapy over a broad range of applications and indications," Emerson added.